Results 101 to 110 of about 4,914,110 (289)

Two Years of Ocrelizumab Treatment in Black and Hispanic People with Multiple Sclerosis in CHIMES: A Single‐Arm Clinical Trial

Annals of Neurology, EarlyView.
Objective To evaluate the effectiveness and safety of ocrelizumab in self‐identified black and Hispanic people with relapsing multiple sclerosis. Methods The Characterization of Ocrelizumab in Minorities with Multiple Sclerosis (CHIMES) trial, a prospective, open‐label, single‐arm, phase 4 study, intentionally recruited underrepresented populations in ...
Lilyana Amezcua, Anthony T. Reder, Evanthia Bernitsas, Nancy L. Monson, Timothy Vartanian, Gregory F. Wu, Mansoor Saleh, Annette Okai, Ahmed Z. Obeidat, Dilraj Sokhi, Rikisha Parekh, Jinglan Pei, Christopher Harp, David Clayton, Ibraheem Abioye, Mitzi J. Williams, for the CHIMES Study Group   +16 more
wiley   +1 more source

MOG antibody-associated demyelinating disease mimicking typical multiple sclerosis: A case for expanding anti-MOG testing?

, 2019
MOG-antibody associated demyelinating disease is a new emerging diagnostic entity. Recently, international recommendations for testing of anti-MOG antibodies were published. Herein, we describe a case of anti-MOG antibody-associated demyelinating disease
Stefanis, L., Angelopoulou, G., Kilidireas, C., Tzanetakos, D., Breza, M., Velonakis, G., Kasselimis, D., Potagas, C., Tzartos, J.S., Karagiorgou, K., Evangelopoulos, M.E., Anagnostouli, M., Koutsis, G.   +12 more
core   +1 more source

Establishing Sensory Neurons as Therapeutic Targets in Peripheral Neuropathy Driven by Polyglutamine Expanded Murine ATXN3

Annals of Neurology, EarlyView.
Repeat expansion disorders frequently involve peripheral neuropathy, yet mechanisms remain unclear. Using a spinocerebellar ataxia type 3 (SCA3) Knock‐In Atxn3Q300/Q6, we identify progressive sensorimotor deficits, peripheral nerve pathology, and dorsal root ganglia RNA splicing dysregulation.
Juan P. Mato, John M. Hayes, Jacen Emerson, Maeha Sridharan, Toluwani Adelaja, Arsal Naeem, Alexandra F. Putka, Hayley S. McLoughlin   +7 more
wiley   +1 more source

A Case of a 40‐year‐old Female with Speech Disturbance

Annals of Clinical and Translational Neurology, EarlyView.
Victoria Lorah, Michael V. Robers
wiley   +1 more source

Using Synthetic Glycans to Investigate Anti‐Glycan Antibodies and Explore Their Medical Potential

Angewandte Chemie International Edition, EarlyView.
Anti‐glycan antibodies are essential in health and disease. Access to novel glycan structures paves the way for progress in antibody profiling for biomarker discovery, antibody development, and vaccine design. We summarize the strategies to synthesize and utilize synthetic glycans for the development and application of anti‐glycan antibodies in basic ...
Fabienne Weber, Aina Valenti, Jiří Ledvinka, Oren Moscovitz, Peter H. Seeberger   +4 more
wiley   +1 more source

Potassium Channel KIR4.1-Specific Antibodies and Acquired Demyelinating Disease

, 2014
Researchers at Technische Universitat, Munich, and other centers in Germany, studied the prevalence of KIR4.1-IgG by ELISA in 47 children with acquired demyelinating disease (ADD), in 22 with other neurologic diseases, 22 with autoimmune disease, and in ...
John J Millichap, J Gordon Millichap
core   +1 more source

Pharmacokinetics, Effectiveness and Safety of Certolizumab Pegol in Children and Adolescents With Active Juvenile Idiopathic Arthritis: 9+‐Year Results From a Multicenter, Open‐Label Study

Arthritis &Rheumatology, EarlyView.
Objective The purpose of this study was to assess the pharmacokinetics, effectiveness, safety, and immunogenicity of certolizumab pegol (CZP) in polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods Pediatric Arthritis Study of Certolizumab Pegol (NCT01550003), a multicenter, open‐label study, enrolled patients aged 2 to 17 years with ...
Hermine I. Brunner, Lyudmila Grebenkina, Irina Nikishina, Ekaterina Alexeeva, Vyacheslav Chasnyk, Carlos Abud‐Mendoza, Nadina Rubio‐Pérez, Heinrike Schmeling, María del Rocio Maldonado‐Velázquez, Diane Brown, Andrew Zeft, Esi Morgan, C. Egla Rabinovich, Daniel Kingsbury, Hulya Bukulmez, Beth Gottlieb, Thomas Griffin, Lisa Imundo, Stacey Tarvin, Earl Silverman, Laura Shaughnessy, Saori Shimizu, Paulette Williams, Rocío Lledó‐García, Gauri Utturkar, Baran Ufuktepe, Alberto Martini, Daniel J. Lovell, Nicolino Ruperto, the Paediatric Rheumatology International Trials Organisation (PRINTO); the Pediatric Rheumatology Collaborative Study Group (PRCSG), Hermine I. Brunner, Lyudmila Grebenkina, Irina Nikishina, Ekaterina Alexeeva, Vyacheslav Chasnyk, Carlos Abud‐Mendoza, Nadina Rubio‐Pérez, Heinrike Schmeling, María del Rocio Maldonado‐Velázquez, Diane Brown, Andrew Zeft, Esi Morgan, C. Egla Rabinovich, Daniel Kingsbury, Hulya Bukulmez, Beth Gottlieb, Thomas Griffin, Lisa Imundo, Stacey Tarvin, Earl Silverman, Alberto Martini, Daniel L. Lovell, Nicolino Ruperto   +52 more
wiley   +1 more source

Familial Hemophagocytic Lymphohistiocytosis Type 3 with Demyelinating CNS Disease

, 2009
A case of familial hemophagocytic lymphohistiocytosis type 3 (FHLH3) presenting in a 3-year-old boy with fulminant demyelinating neurological disease is reported by researchers at Kravis Children’s Hospital at Mount Sinai Medical Center, New ...
J Gordon Millichap
core   +1 more source

Exploring Healthcare Continuity in Pediatric‐Onset Multiple Sclerosis in the United States

Annals of the Child Neurology Society, EarlyView.
ABSTRACT Objective Little is known about shifting from pediatric to adult‐focused multiple sclerosis (MS) care. This study aims to explore transition of care and follow‐up in the US pediatric‐onset MS (POMS) population. Methods Surveys were distributed to 10 sites in the US Network of Pediatric MS Centers (US NPMSC) about transition‐of‐care practices ...
Aaron W. Abrams, Michael Waltz, Jonathan Race, T. Charles Casper, Claudia Gambrah‐Lyles, Kimberly O'Neill, Akash Virupakshaiah, Kristen S. Fisher, Melissa A. Wright, Kelsey E. Poisson, Eva‐Chava M. Bernfeld, Gregory Aaen, Leslie A. Benson, Tanuja Chitnis, Carla Francisco, Grace Y. Gombolay, Mark P. Gorman, Jennifer S. Graves, Lauren Krupp, Timothy E. Lotze, Soe Mar, Jayne Ness, Mary Rensel, Moses Rodriguez, Teri Schreiner, Nikita Shukla, Jan‐Mendelt Tillema, Bianca Weinstock‐Guttman, Yolanda Wheeler, Emmanuelle Waubant, John Rose, US Network of Pediatric MS Centers   +31 more
wiley   +1 more source

Longitudinal Clinical Progression in X‐Linked Adrenoleukodystrophy: The AMNL Scoring System

Annals of the Child Neurology Society, EarlyView.
ABSTRACT Objective The current clinical nomenclature for individuals with ABCD1 gene dysfunction is often uninformative. The disorder was initially described as a combination of adrenal insufficiency and leukodystrophy, leading to the widespread use of “X‐linked adrenoleukodystrophy” (ALD).
Eda G. Kabak, Cecilie Videbaek, Marije M. C. Voermans, Björn M. van Geel, Keith van Haren, Stephan Kemp, Diederik van de Beek, Marc Engelen   +7 more
wiley   +1 more source